Acesso livre
Acesso livre

Tumores Gastrintestinais

Seguimento pós-estudo | Bursectomia vs. omentectomia isolada para câncer gástrico ressecável.

13 Dez, 2022 | 14:59h

Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001) – British Journal of Surgery (link para o resumo – $ para o texto completo)

 

Benefícios de 15 anos do rastreamento por sigmoidoscopia na incidência e na mortalidade de câncer colorretal: análise agrupada de estudos randomizados.

17 Out, 2022 | 13:34h

15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality: A Pooled Analysis of Randomized Trials – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: One sigmoidoscopy significantly reduces long-term CRC incidence in both men and women – American College of Physicians

Conteúdos relacionados:

RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.

RCT: One-time flexible sigmoidoscopy screening is associated with long-term reduction in colorectal cancer incidence and mortality.

ACP Guideline: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults

BMJ Guideline: Colorectal Cancer Screening with Fecal Immunochemical Testing, Sigmoidoscopy or Colonoscopy

Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (se o acesso a este link for pago, tente este em PMC)

Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

 

Comentário no Twitter

 

Estudo randomizado | Efeito do rastreamento com colonoscopia sobre os riscos de câncer colorretal e morte relacionada.

17 Out, 2022 | 12:59h

Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentários:

In gold-standard trial, invitation to colonoscopy reduced cancer incidence but not death – STAT

New study examines the effectiveness of colonoscopies – CNN

 

Podcast | Pólipos, polipectomia e vigilância.

6 Out, 2022 | 12:36h

Polyps, polypectomy & surveillance with Dr. Jennifer Maranki – The Curbsiders

 

Estudo de coorte | A taxa de detecção de adenoma após teste fecal imunoquímico (fecal immunochemical test – FIT) positivo está associada a risco de câncer colorretal no intervalo pós-colonoscopia.

6 Out, 2022 | 12:34h

Adenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test–Based Screening: A Population-Based Cohort Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

Comentários:

Colonoscopies in FIT-positive persons requires much higher ADR than primary colonoscopy – American College of Physicians – American College of Physicians

Adenoma Detection Rate Tied to CRC Risk After Positive FIT – HealthDay

 

Comentário no Twitter

 

Estudo de coorte | Calculadora clínica para câncer retal pode estimar a recorrência após terapia neoadjuvante com ou sem cirurgia.

3 Out, 2022 | 12:46h

A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management – JAMA Network Open

Comentário convidado: A Clinical Calculator in the Era of Nonoperative Management for Rectal Cancer—How Should We Intensify or Deescalate Surveillance? – JAMA Network Open

 

Diretriz prática AASLD sobre colangite esclerosante primária e colangiocarcinoma.

13 Set, 2022 | 12:02h

AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology

 

Estudo randomizado | Ripretinibe vs. sunitinibe em pacientes com tumor estromal gastrintestinal avançado após tratamento com imatinibe.

12 Set, 2022 | 11:08h

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Editorial: Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine – Journal of Clinical Oncology

 

Comentário no Twitter

 

Estudo de braço único fase 2 | Galunisertibe com quimioterapia neoadjuvante em pacientes com câncer retal localmente avançado.

8 Set, 2022 | 13:42h

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentários:

Addition of Galunisertib to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer – The ASCO Post

Improved Complete Response Rate Observed With Galunisertib Plus Neoadjuvant CRT in Advanced Rectal Cancer – Cancer Network

 

Seguimento de 5 anos de estudo randomizado | FOLFIRINOX vs. gencitabina como terapia adjuvante no câncer pancreático.

6 Set, 2022 | 13:00h

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.